- Home
- AMLX vs ANAB Comparison
AMLX vs ANAB Comparison
Compare AMLX & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMLX | ANAB |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | AMLX | ANAB |
|---|---|---|
| Price | $14.22 | $45.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $17.43 | ★ $58.09 |
| AVG Volume (30 Days) | ★ 1.7M | 542.0K |
| Earning Date | 03-03-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $169,467,000.00 |
| Revenue This Year | N/A | $135.51 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 196.42 |
| 52 Week Low | $2.60 | $12.21 |
| 52 Week High | $16.96 | $52.47 |
Technical Indicators
Market Signals| Indicator | AMLX | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 64.81 | 50.32 |
| Support Level | $12.08 | $42.50 |
| Resistance Level | $12.50 | $50.50 |
| Average True Range (ATR) | 0.74 | 3.18 |
| MACD | 0.32 | -0.30 |
| Stochastic Oscillator | 89.40 | 37.92 |
Price Performance
Historical ComparisonAbout AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).